Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
LENZ
LENZ
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
LENZ News
FDA Approves Tenpoint's New Eye Drop for Presbyopia
Jan 30 2026
Benzinga
FDA Approves Tenpoint's Eye Drops, Competing with LENZ
Jan 30 2026
Newsfilter
LENZ Therapeutics Under Investigation, Stock Plummets 26%
Jan 20 2026
Globenewswire
LENZ Launches VIZZ Eye Drops, Restoring Near Vision for Up to 10 Hours
Jan 14 2026
Newsfilter
LENZ Therapeutics Under Investigation, Stock Plummets 26%
Jan 13 2026
Globenewswire
LENZ Therapeutics Faces Investigation After VIZZ Eye Drop Incident, Stock Plummets 26%
Jan 08 2026
PRnewswire
LENZ Secures FDA Approval for VIZZ Eye Drops, Reports $1.6M Q4 Revenue
Jan 08 2026
NASDAQ.COM
LENZ Launches VIZZ Eye Drops, Achieves $1.6 Million in First Quarter Revenue
Jan 07 2026
Globenewswire
LENZ Therapeutics Partners with Lunatus for Exclusive VIZZ Distribution in Middle East
Jan 05 2026
Newsfilter
LENZ Therapeutics Faces Investigation After 26% Stock Drop Linked to Eye Drop Incident
Jan 01 2026
PRnewswire
LENZ Therapeutics Faces 26% Stock Drop Following Retinal Tear Incident
Dec 30 2025
Globenewswire
LENZ Shares Drop Following Negative Report on Eye Treatment
Dec 12 2025
SeekingAlpha
Lotus Pharma, Partner of LENZ Therapeutics, Pursues Approval for VIZZ to Address Presbyopia in South Korea
Dec 02 2025
NASDAQ.COM
Top Analysts Recommend 3 Best Stocks to Purchase as of December 1, 2025
Dec 01 2025
TipRanks
LENZ Therapeutics Announces Financial Results and Key Developments for Q3 2025
Nov 05 2025
Newsfilter
LENZ Therapeutics, Inc. (LENZ) Receives Upgrade to Buy: Implications for the Stock
Oct 22 2025
NASDAQ.COM
Show More News
